Summarized by Masters of Longevity from Longevity Technology.
ProMIS licensed Ossianix's TXP1 brain-selective shuttle targeting transferrin receptor 1.

Key Takeaways
- ProMIS licensed TXP1 to enhance CNS delivery of its drug.
- TXP1 targets transferrin receptor 1 to shuttle therapies into brain.
- Enhanced delivery may improve drug brain levels but is unproven.



